For a 40‑year‑old patient with autism spectrum disorder and binge‑eating disorder who is currently taking Vyvanse (lisdexamfetamine), what additional treatment options do you recommend?

Treatment Recommendations for Binge-Eating Disorder in a 40-Year-Old with ASD on Vyvanse

Your patient should be receiving eating disorder-focused cognitive-behavioral therapy (CBT) or interpersonal therapy as the primary treatment, with Vyvanse serving as an adjunct. 1

Primary Treatment Approach

The 2023 APA guidelines make clear that psychotherapy is the foundation of BED treatment 1. Specifically:

• Eating disorder-focused CBT or interpersonal therapy (individual or group format) is the recommended first-line treatment (1C recommendation) 1
• Medication like lisdexamfetamine (Vyvanse) is suggested only for patients who prefer medication or have not responded to psychotherapy alone (2C suggestion) 1

Since your patient is already on Vyvanse, the critical question is whether they're receiving evidence-based psychotherapy. If not, this is the most important gap to address.

Optimizing Current Medication Management

Vyvanse dosing for BED: The FDA-approved regimen starts at 30 mg daily, titrating by 20 mg weekly to a target of 50-70 mg/day (maximum 70 mg/day) 2. Ensure your patient is at an adequate therapeutic dose—recent meta-analysis confirms significant efficacy in reducing binge-eating frequency (average 1.29 fewer binge days per week) and obsessive-compulsive eating behaviors 3.

Critical monitoring requirements given the ASD comorbidity:

• Cardiovascular: Blood pressure and heart rate monitoring 2
• Psychiatric screening: Patients with ASD may have heightened risk for stimulant-induced anxiety, agitation, or mood destabilization 2
• Growth/weight: While weight loss is expected in BED treatment with Vyvanse (average 1.31 SMD reduction) 3, monitor for excessive weight loss
• Tics/stereotypies: Assess for emergence or worsening, as stimulants can exacerbate these 2

Additional Pharmacological Options

If Vyvanse alone proves insufficient despite adequate dosing and psychotherapy:

Combination therapy: The most recent high-quality evidence (2025 RCT) demonstrates that CBT + lisdexamfetamine is superior to either treatment alone, achieving 70.2% remission rates versus 44.7% for CBT alone or 40.4% for LDX alone 4. This supports augmenting Vyvanse with structured psychotherapy rather than adding another medication.

Alternative medications if Vyvanse is not tolerated or contraindicated:

• Topiramate: Evidence supports efficacy for BED, though not FDA-approved 5
• SSRIs (fluoxetine, sertraline, citalopram): Particularly useful if comorbid depression or anxiety 5
• GLP-1 agonists (semaglutide, liraglutide): Emerging evidence shows promise for reducing binge eating in individuals with obesity, though data specific to BED is limited 5, 6

Avoid: Atypical antipsychotics (olanzapine, clozapine), mirtazapine, tricyclic antidepressants, and valproate due to weight gain risk 5

Addressing ASD-Specific Considerations

The comorbidity of ASD and BED is clinically significant: Recent 2026 data shows that individuals with both conditions have substantially elevated odds of maladaptive eating behaviors (AORs 3.18-5.85) compared to those with neither condition 7. This suggests your patient may have more severe or treatment-resistant symptoms.

Practical implications:

• Sensory sensitivities common in ASD may complicate dietary interventions
• Rigid thinking patterns may require adapted CBT approaches
• Social communication challenges may necessitate individual rather than group therapy formats
• Consider whether ADHD symptoms are adequately controlled, as untreated ADHD exacerbates eating pathology 7

Comprehensive Treatment Plan Structure

Essential components per APA guidelines 1:

1. Multidisciplinary coordination: Medical, psychiatric, psychological, and nutritional expertise 1
2. Regular monitoring: Quantify binge-eating frequency, weight, vital signs 1
3. Laboratory surveillance: CBC, comprehensive metabolic panel (electrolytes, liver, renal function) 1
4. ECG monitoring: Required for patients on QTc-prolonging medications like stimulants 1

Common Pitfalls to Avoid

• Medication monotherapy: Using Vyvanse without psychotherapy contradicts guideline recommendations and limits treatment efficacy 1
• Inadequate dosing: Failing to titrate Vyvanse to the 50-70 mg therapeutic range for BED 2
• Ignoring cardiovascular risk: Stimulants carry serious cardiac risks; screen for structural heart disease before initiating and monitor throughout 2
• Overlooking comorbidities: Depression, anxiety, and ADHD frequently co-occur with BED and may require targeted treatment 5
• Weight-gain inducing medications: Avoid agents that worsen the metabolic consequences of BED 5

The evidence strongly supports that your patient needs structured eating disorder-focused psychotherapy as the cornerstone of treatment, with Vyvanse serving as a valuable but secondary intervention.